Codexis, Inc. provided revenue guidance for the full year of 2022. Total revenues are expected to be in the range of $152 million to $158 million, an increase of nearly 50% at the midpoint compared to 2021; excluding revenue from Pfizer in both periods, revenue growth is projected to be 10% or more.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.22 USD | -7.20% | -14.59% | +5.57% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.57% | 227M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+45.83% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- CDXS Stock
- News Codexis, Inc.
- Codexis, Inc. Provides Revenue Guidance for the Full Year of 2022